No idea. The positive remarks only referenced the Striate deal and the possibility that the company could be self-sustaining with respect to funding from here on, but could have generated a bit of further investigation by motivated budding investors. I suspect a couple of years ago results like this would have put a rocket under the share price.
Now, not so much.
Ann: Successful OrthoATI clinical trial, page-36
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.40M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 36.5¢ | 36.5¢ | $7.753K | 21.24K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 53033 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 48304 | 2 |
View Market Depth
| Last trade - 15.24pm 03/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |